Containers - Adult
Red Cap Tube EDTA KE 9ml
10-15 ml peripheral blood, bone marrow specimen or FFPE tissue
Additive per Container
Specimens should ideally arrive within 24 hours of collection (maximum of 48 hours) and should be sent to the following address:
Western General Hospital
Haematology/Biochemistry Combined Reception
See also Specimen transportation.
Sample storage arrangements
Samples should be stored at room temperature. See specimen requirements.
How to request
Please refer to our detailed requesting instructions. The HMDS request form can be located here.
Testing may be performed by reflex from immunophenotyping.
Results should be expected within 5 working days. See results.
FLT3 (both ITD and point mutation D835) gene mutation analysis performed for all patients diagnosed with AML based on immunophenotyping results via a reflex testing strategy.
FLT3 mutation is not a reliable marker for MRD monitoring within AML
General additional information
FLT3 is the most commonly mutated gene in AML and detected in one third of AML cases. Internal tandem duplications (ITDs) in the juxtamembrane domain of FLT3 are seen in 25% of AML cases, while others show mutations in the tyrosine kinase domain of FLT3 gene.
Where FLT3 ITD mutation detected, the mutant allele ratio of the ITD mutation can be calculated. The presence of a high level of FLT3 ITD mutation in the absence of a NPM1 mutation is associated with an adverse prognosis in AML.
NPM1 mutation detection is also available for AML patients at diagnosis.
This test is accredited to ISO 15189:2012
For clinical advice on appropriate investigations and advice for the interpretation of test results, please contact us.